NEWS

WIRES

OTHER

Christopher J. Pugh Joins Genitrix, LLC as Vice President, Business Development

Genitrix, LLC announced today that Christopher J. Pugh has joined the Company as Vice President, Business Development. Mr. Pugh previously served as Vice President, Business Development at Bioject, which develops and markets novel delivery systems for vaccines and therapeutics. While at Bioject he negotiated a number of external agreements, including one that offered the largest potential payout in that company's 18-year history. Prior to that, he was Director of Business Development at Guilford Pharmaceuticals, which develops and markets therapeutics for cancer and other serious conditions. Before joining Guilford he held positions in the vaccine divisions of Merck and SmithKline. Mr. Pugh began his career at Procter & Gamble Pharmaceuticals.

Commenting on his appointment, Mr. Pugh said, "I am delighted to be joining Genitrix, an exciting company that is at a particularly exciting point in its development. I am especially impressed with the potency, practicality, and versatility of the Opsonokine™ technology. The ability of the Company's lead molecule to rapidly stimulate a robust cytotoxic T cell response opens up a range of commercial opportunities in the immunotherapy of infectious diseases and cancer."

"We are extremely pleased that Chris has accepted this position," said Andrew H. Segal, M.D., President and CEO of Genitrix. "His experience in both vaccines and oncology make him an ideal fit for us. Furthermore, he brings to Genitrix the wealth of knowledge and perspective he has acquired in his work at Merck, SmithKline, Bioject, and Guilford. We look forward to benefiting from his initiative and his expertise."

Genitrix, LLC, a privately held biotechnology company headquartered in Cambridge, MA, is developing innovative immunotherapeutic products based on its powerful Opsonokine™ technology. Opsonokines are "sticky" cytokines that attach to cells automatically, on contact, making it possible to put the right cytokine in the right place in the right amount, and keep it there. The Company's lead Opsonokine™ molecule overcomes the "immunogenicity barrier," historically a major obstacle to immunotherapy, by targeting the body's critical "antigen presenting cells" and stimulating a potent cytotoxic T cell response. Genitrix is currently developing products, based on this lead molecule, for the treatment of cancer and chronic viral infections.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. Such forward-looking statements are based on the beliefs of Genitrix's management, as well as assumptions made by and information currently available to the Genitrix's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; intellectual property conflicts and disputes; and many other risk factors. Genitrix and its management undertake no obligation to revise any forward-looking statements as a result of future events or developments.

Distributed by Market Wire